Skip to main content
logo
Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
81.20
-4.40 (-5.14%)
At close: Mar 27, 2026

TPE:6919 Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
38.0444.4338.9312.8212.34
Revenue Growth (YoY)
-14.40%14.13%203.68%3.90%19.22%
Cost of Revenue
11.5213.6711.463.213.11
Gross Profit
26.5230.7627.479.619.23
Selling, General & Admin
83.2197.7936.9534.2159.35
Research & Development
650.54650.12503.99295.02180.62
Operating Expenses
733.74747.91540.94329.23239.97
Operating Income
-707.22-717.14-513.47-319.62-230.73
Interest Expense
-0.16-0.33-0.5-0.67-2.9
Interest & Investment Income
233.0774.2117.425.190.1
Currency Exchange Gain (Loss)
122.738.63-1.0314.23-1.07
Other Non Operating Income (Expenses)
-0.3115.819.1214.8310.34
EBT Excluding Unusual Items
-351.92-588.83-488.46-286.05-224.26
Gain (Loss) on Sale of Assets
----0.11-
Pretax Income
-351.92-588.83-488.46-286.16-224.26
Income Tax Expense
----0.03
Net Income
-351.92-588.83-488.46-286.16-224.29
Net Income to Common
-351.92-588.83-488.46-286.16-224.29
Shares Outstanding (Basic)
1,5431,4301,2391,171920
Shares Outstanding (Diluted)
1,5431,4301,2391,171920
Shares Change (YoY)
7.94%15.40%5.77%27.35%23.49%
EPS (Basic)
-0.23-0.41-0.39-0.24-0.24
EPS (Diluted)
-0.23-0.41-0.39-0.24-0.24
Free Cash Flow
-442.43-532.31-432.54-256.93-125.6
Free Cash Flow Per Share
-0.29-0.37-0.35-0.22-0.14
Gross Margin
69.72%69.23%70.56%74.94%74.83%
Operating Margin
-1859.31%-1613.95%-1318.88%-2493.17%-1869.95%
Profit Margin
-925.20%-1325.18%-1254.64%-2232.10%-1817.76%
Free Cash Flow Margin
-1163.16%-1197.97%-1111.01%-2004.12%-1017.90%
EBITDA
-684.64-695.71-493.68-302.36-214.49
D&A For EBITDA
22.5821.4319.7917.2616.24
EBIT
-707.22-717.14-513.47-319.62-230.73
Advertising Expenses
--0.06--
Source: S&P Global Market Intelligence. Standard template. Financial Sources.